{"product_id":"rxrx-ansoff-analysis","title":"(RXRX) Recursion Pharmaceuticals, Inc. ANSOFF Analysis Research","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-List-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDive Deeper Into the Growth Paths Behind the Analysis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eThis Recursion Pharmaceuticals, Inc. Ansoff Matrix Analysis maps the company’s growth options across market penetration, market development, product development, and diversification and is used to guide strategic, investment, or R\u0026amp;D decisions; this page already contains a real preview of the analysis so you can review style and substance before buying. Purchase the full version to receive the complete, ready-to-use Ansoff Matrix tailored to Recursion.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Penetration\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-994 Phase IIa cerebral cavernous malformation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-994’s Phase IIa cerebral cavernous malformation program is a clear market penetration move: Recursion is deepening its position in the same rare-disease space with the same asset. The focus is now on enrollment, site execution, and data quality, not new-market expansion. That fits a current development market where speed and trial delivery drive visibility.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-3599 Phase I GM2 gangliosidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-3599’s Phase I program in GM2 gangliosidosis supports market penetration by deepening Recursion Pharmaceuticals, Inc.’s presence in an ultra-rare neurology niche without changing the asset. GM2 gangliosidosis is an ultra-rare lysosomal storage disease, so even one ongoing study can strengthen scientific visibility, site relationships, and patient-finding capability. Continued dose, safety, and biomarker progress in Phase I helps Recursion build trust around the same molecule and broaden its footprint in rare CNS disorders.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Penetration-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-2282 neurofibromatosis type 2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-2282 deepens Recursion Pharmaceuticals, Inc.'s reach in the NF2 rare-disease niche, where NF2 affects about 1 in 25,000 to 33,000 people. As a current clinical-stage asset, it keeps the Company in the same patient pool while it builds treatment use, site know-how, and investigator loyalty. That matters in a small market, where even one more enrolled trial can strengthen access and retention.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eREC-4881 familial adenomatous polyposis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-4881 gives Recursion Pharmaceuticals, Inc. a clear foothold in familial adenomatous polyposis, a rare GI market with roughly 1 in 8,000 to 1 in 10,000 people affected. Market penetration here means putting more development weight behind one existing asset, not expanding into a new disease area.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eStrengthens an existing rare-disease position\u003c\/li\u003e\n\u003cli\u003eTargets a narrow, clinically defined market\u003c\/li\u003e\n\u003cli\u003ePenetration = deeper program investment\u003c\/li\u003e\n\u003cli\u003eFits Recursion’s oncology and GI focus\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eCurrent clinical-stage rare-disease portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. is using its current Phase I and Phase IIa rare-disease assets as the base for market share gains in development-stage orphan markets. The portfolio covers 4 programs: cerebral cavernous malformation, GM2 gangliosidosis, NF2, and familial adenomatous polyposis, so capital stays focused on existing demand pockets before wider expansion.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e4 clinical rare-disease assets\u003c\/li\u003e\n\u003cli\u003ePhase I and Phase IIa base\u003c\/li\u003e\n\u003cli\u003eFocus: current markets first\u003c\/li\u003e\n\u003cli\u003eExpansion comes after validation\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion Deepens Its Grip on Ultra-Rare Disease Markets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. is using its 4 ongoing rare-disease programs to push deeper into the same patient pools, not enter new ones. That is market penetration: more focus on current assets, tighter site execution, and stronger investigator reach in ultra-rare markets like NF2 and FAP.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eStage\u003c\/th\u003e\n\u003cth\u003eMarket\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-994\u003c\/td\u003e\n\u003ctd\u003ePhase IIa\u003c\/td\u003e\n\u003ctd\u003eCCM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-3599\u003c\/td\u003e\n\u003ctd\u003ePhase I\u003c\/td\u003e\n\u003ctd\u003eGM2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"product-includes\"\u003e\n\u003cdiv class=\"product-includes__container\"\u003e\n\u003ch2 id=\"product-includes-title\" class=\"product-includes__title\"\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-includes__grid\"\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Detailed Word Document icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eOutlines Recursion Pharmaceuticals, Inc.’s growth options across existing and new products and markets\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Customizable Excel Spreadsheet icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eEditable Excel File\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a quick Ansoff Matrix view for Recursion Pharmaceuticals, Inc. to simplify growth strategy decisions across drugs, data, and new markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"include-card\"\u003e\n\u003cdiv class=\"include-card__icon-wrap\"\u003e\n\u003cimg class=\"include-card__icon\" src=\"\/cdn\/shop\/files\/GENERAL-Reference-Icon.svg\" alt=\"References icon\"\u003e\n\u003c\/div\u003e\n\u003ch3 class=\"include-card__heading\"\u003e\u003cstrong\u003eReference Sources\u003c\/strong\u003e\u003c\/h3\u003e\n\u003cp class=\"include-card__text\"\u003eProvides a concise, traceable bibliography of primary and reputable sources to validate Recursion Pharmaceuticals' Ansoff Matrix growth assumptions for faster due diligence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eMarket Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eBayer AG collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. uses its Bayer AG partnership to push beyond Salt Lake City and reach Bayer’s global development network. The alliance, announced as a deal worth up to $1.5 billion in milestones and royalties, lets Recursion keep its core AI platform and pipeline while using a much larger external channel. That widens reach without adding new core assets or sites.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTakeda Pharmaceutical Company Limited collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eTakeda Pharmaceutical Company Limited collaboration can widen Recursion Pharmaceuticals, Inc. market development by adding partner-led R\u0026amp;D routes to its existing pipeline, so each program can move through more channels than Recursion could fund alone. Recursion already uses an external collaboration model, and Takeda helps extend that playbook across more assets, which matters as the company targets broader development and commercialization reach. The value is scale: more partnered programs, more shots on goal, and more non-dilutive capital tied to shared R\u0026amp;D execution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Market-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eUniversity of Utah Research Foundation collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. uses the University of Utah Research Foundation collaboration to widen academic-market reach through the University of Utah network, adding another translational R\u0026amp;D channel without changing its core platform. In 2025, Recursion reported $58.0 million in revenue and $619.5 million in cash, giving it room to push the platform into new research settings.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eOhio State Innovation Foundation collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eOhio State Innovation Foundation strengthens Recursion Pharmaceuticals, Inc.’s market development by widening access to a major academic and clinical ecosystem. One large research partner can improve platform reach, since Ohio State helps open more translational studies, patient links, and discovery channels. This fits Ansoff market development: same platform, broader institutional footprint.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExpands reach through one major university partner\u003c\/li\u003e\n\u003cli\u003eSupports more research and clinical pathways\u003c\/li\u003e\n\u003cli\u003eScales the same platform without new core tech\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eChromaderm, Inc. collaboration\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eChromaderm, Inc. gives Recursion Pharmaceuticals, Inc. a new external development partner, which fits Ansoff’s market development move. The deal widens discovery and validation beyond Recursion’s core headquarters base, so its AI-enabled drug engine can reach more use cases and partners. This matters because Recursion can extend existing capabilities into a broader network without building every new path in-house.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cp\u003eNew partner, not a new product.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eExpands discovery outside core labs.\u003c\/p\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cp\u003eBuilds wider validation access.\u003c\/p\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion Scales AI Drug Reach Through Partner Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. drives market development by using partner networks like Bayer AG and Takeda Pharmaceutical Company Limited to push the same AI drug platform into more geographies and research channels. In 2025, Recursion reported $58.0 million revenue and $619.5 million cash, giving it room to scale external reach without new core sites.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$58.0 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$619.5 million\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket development lever\u003c\/td\u003e\n\u003ctd\u003ePartner networks\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eRecursion Pharmaceuticals, Inc. Reference Sources\u003c\/h2\u003e\n\u003cp\u003eThis is the actual Ansoff Matrix analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full report you'll get; purchase unlocks the complete, editable version with detailed market, product, risk, and strategic recommendations tailored to Recursion Pharmaceuticals, Inc.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eProduct Development\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-65029 HRD-negative ovarian cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-65029 HRD-negative ovarian cancer is a new oncology molecule in Recursion Pharmaceuticals, Inc.'s pipeline, so it fits Product Development in the Ansoff Matrix by extending a current cancer focus into a defined tumor segment. HRD-negative ovarian cancer remains a large unmet need, with about 314,000 new ovarian cancer cases and 207,000 deaths worldwide in 2022. This adds depth to Recursion Pharmaceuticals, Inc.'s oncology set without moving into a new market.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-2029 wnt-mutant hepatocellular carcinoma\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-2029 widens Recursion Pharmaceuticals, Inc.'s oncology portfolio by adding a targeted hepatocellular carcinoma program, so it is clear product expansion. The wnt-mutant liver cancer focus fits the Company Name's existing cancer-first development model and keeps it inside a familiar biology lane. This supports a broader pipeline strategy without stepping outside its core oncology focus.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Product-Development-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-14221 solid and hematological malignancies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-14221 broadens Recursion Pharmaceuticals, Inc.’s oncology mix by targeting both solid and hematological malignancies, so it can fit more cancer settings with one asset. In Ansoff terms, this is product development: a new product for an existing therapeutic market. The bigger reach across solid tumors and blood cancers can deepen market coverage without leaving oncology.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eREC-64151 KRAS\/STK11 mutant non-small cell lung cancer\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-64151 adds depth to Recursion Pharmaceuticals, Inc.’s precision oncology push by targeting a KRAS\/STK11-mutant NSCLC subgroup tied to immune checkpoint resistance. NSCLC is about 85% of lung cancers, and KRAS mutations show up in roughly 25% of lung adenocarcinomas, with STK11 often marking poorer immunotherapy response.\u003c\/p\u003e\n\u003cp\u003eIn Ansoff terms, this is a product-development move: a new oncology asset for an existing cancer market. It broadens the pipeline with a biomarker-defined program that can support more selective trial design and cleaner clinical signals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePrecision oncology depth\u003c\/li\u003e\n\u003cli\u003eCheckpoint-resistant NSCLC niche\u003c\/li\u003e\n\u003cli\u003eNew product, current market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eREC-648918 anti-tumor immunity\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-648918 is an immuno-oncology extension that aims to boost anti-tumor immunity, fitting Recursion Pharmaceuticals, Inc.'s oncology focus and adding a differentiated asset to its cancer pipeline. With cancer causing about 10 million deaths a year worldwide, immune-focused programs target a huge unmet need and can widen the company's reach beyond core platforms.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eExtends oncology into immuno-oncology\u003c\/li\u003e\n\u003cli\u003eTargets anti-tumor immune activation\u003c\/li\u003e\n\u003cli\u003eAdds a differentiated new asset\u003c\/li\u003e\n\u003cli\u003eSupports a large cancer market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion Expands Its Cancer Pipeline With New Targeted Oncology Assets\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc.’s product development move is to add new oncology assets to an existing cancer base, not to enter a new market. REC-65029, REC-2029, REC-14221, REC-64151, and REC-648918 all widen the pipeline in defined tumor or biomarker groups, including HRD-negative ovarian cancer and KRAS\/STK11-mutant NSCLC. That fits a new-product, current-market play.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eAsset\u003c\/th\u003e\n\u003cth\u003eFit\u003c\/th\u003e\n\u003cth\u003eKey point\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-65029\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003ctd\u003eHRD-negative ovarian cancer\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-64151\u003c\/td\u003e\n\u003ctd\u003eProduct development\u003c\/td\u003e\n\u003ctd\u003eKRAS\/STK11-mutant NSCLC\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-wrapper\"\u003e\n\u003cdiv class=\"container_new_design pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"sub-highlight-wrapper_heading\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Icon-1.svg\" alt=\"Icon\"\u003e\n\u003ch2\u003eDiversification\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-3964 C. difficile colitis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-3964 pushes Recursion Pharmaceuticals, Inc. into infectious disease, a clear move beyond its rare-disease and oncology core. C. difficile colitis is a separate market with about 462,000 U.S. infections and 29,300 deaths in 2017, so the asset widens therapeutic spread with a new product in a new area. That makes this a diversification play, not just a pipeline add-on.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-64917 neural\/systemic inflammation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-64917 moves Recursion Pharmaceuticals, Inc. into inflammation biology as a separate market, not just a cancer play. That matters because it broadens the platform beyond its oncology-heavy base and adds a new therapeutic lane with distinct disease biology, target selection, and clinical readouts. In Ansoff terms, it is diversification: a new product class for a new disease area.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/ANSOFF-Content-Diversification-Image.png\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eREC-3599 GM2 gangliosidosis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eREC-3599 pushes Recursion Pharmaceuticals, Inc. into ultra-rare neurology with GM2 gangliosidosis, a separate patient group with its own biology, trial design, and regulatory path. GM2 is inherited, progressive, and often fatal in early childhood, so it opens a distinct market from Recursion’s other rare-disease programs. That broadens exposure across rare-disease segments and lowers reliance on one indication.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eREC-2282 neurofibromatosis type 2\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-2282 in neurofibromatosis type 2 (NF2) moves Recursion Pharmaceuticals, Inc. beyond oncology into a second rare neurological market, and NF2 affects about 1 in 25,000 people. It adds a distinct clinical-development lane while using the same data and AI platform, so disease risk is broader without building a new engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eSecond rare neuro market beyond oncology\u003c\/li\u003e\n\u003cli\u003eOne platform, broader disease diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003ch3\u003eREC-4881 familial adenomatous polyposis\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eREC-4881 moves Recursion Pharmaceuticals, Inc. into hereditary gastrointestinal disease, a clear diversification step beyond its cancer and neurology programs. Familial adenomatous polyposis is rare, affecting about 1 in 8,000 to 1 in 10,000 people, so it sits in a distinct market with different clinicians, patients, and trial paths. That broadens Recursion Pharmaceuticals, Inc. across multiple therapeutic classes and lowers single-portfolio concentration.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eNew hereditary GI market\u003c\/li\u003e\n\u003cli\u003eSeparate from oncology and neurology\u003c\/li\u003e\n\u003cli\u003eSupports multi-class diversification\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-box-border\"\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Checkmark-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRecursion Expands Beyond Oncology With a Broader, Lower-Risk Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eRecursion Pharmaceuticals, Inc. is using diversification to spread beyond oncology into infectious disease, inflammation, neurology, and hereditary GI disease. REC-3964, REC-64917, REC-3599, REC-2282, and REC-4881 each target a separate market, which lowers single-therapy risk and widens the pipeline. The move is platform-led, but the commercial and clinical bets are now much broader.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eProgram\u003c\/th\u003e\n\u003cth\u003eNew market\u003c\/th\u003e\n\u003cth\u003eSignal\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-3964\u003c\/td\u003e\n\u003ctd\u003eC. difficile\u003c\/td\u003e\n\u003ctd\u003eInfectious disease\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-64917\u003c\/td\u003e\n\u003ctd\u003eInflammation\u003c\/td\u003e\n\u003ctd\u003eNew therapeutic lane\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eREC-3599\u003c\/td\u003e\n\u003ctd\u003eGM2\u003c\/td\u003e\n\u003ctd\u003eUltra-rare neurology\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"DCF Analyst","offers":[{"title":"Default Title","offer_id":57234974179593,"sku":"rxrx-ansoff-analysis","price":5.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0942\/8045\/0313\/files\/rxrx-ansoff-matrix.webp?v=1785730666","url":"https:\/\/dcfanalyst.com\/products\/rxrx-ansoff-analysis","provider":"DCF Analyst","version":"1.0","type":"link"}